Total Credits: .75 including 0.75 AOA Category 1-A Credit(s)
Learning Objectives:
· Discuss older trials supporting risk of diabetes related complications
· Look at new evidence and guidelines for management
· Physiology of SGLT-2 inhibitors, GLP-1 agonist, and GLP-1/GIP agonist
· Medication options for the above classes of medications
· Improvement in outcomes with new therapies
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Ohio Osteopathic Foundation (OOF) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
Grievance Policy: The OOF strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to OOA Director of Education Teri Collins, by calling the OOF Office at 614-299-2107 or by mail to OOF, PO Box 8130, Columbus OH 43201, or by email to tcollins@ohiodo.org.
| Outcome Altering Diabetes Medications (3.1 MB) | 28 Pages | Available after Purchase |
Allison M. Petznick, DO, is board-certified in Family Medicine and Osteopathic Manipulative Treatment. She graduated from Ohio University College of Osteopathic Medicine in 2006. She completed her family medicine residency at Firelands Regional Medical Center in Sandusky, Ohio, along with a diabetes fellowship at Cornwell Diabetes Center in Athens, Ohio. She is affiliated with NOMS Family Medicine in Sandusky, Ohio.
Dr. Petznick has no disclosures.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|